Abstract
Mitochondria are produced from the transcription and translation of genes both in the nuclear genome and in the mitochondrial genome, termed mitobiogenesis. Measuring mitobiogenesis is useful for early toxicity screening of new drug candidates. This requires an assay that is quantitative, specific, and reproducible and is also flexible enough to be applied in a variety of cell types.
Similar content being viewed by others
Literatur
Food and Drug Administration (2006) Guidance for Industry; Antiviral Product Development — Conducting and Submitting Virology Studies to the Agency. www.fda.gov/OHRMS/DOCKETS/98fr/05d-0183-gdl0002-01.pdf
Food and Drug Administration (2009) Guidance for Industry; Drug-Induced Liver Injury: Premarketing Clinical Evaluation. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf
Medeiros, DM (2008) Assessing mitochondria biogenesis. Methods 46:288–294
Author information
Authors and Affiliations
Corresponding author
Additional information
James Murray, Daniel Schwartz und Jan Hryca (v. l. n. r.)
Rights and permissions
About this article
Cite this article
Murray, J., Schwartz, D. & Hryca, J. Bestimmung der Inhibition der mitochondrialen Biogenese. Biospektrum 18, 60–61 (2012). https://doi.org/10.1007/s12268-012-0145-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12268-012-0145-4